Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Scientists identify potent and selective IDE inhibitors with a new mode of action

June 21, 2010

Japanese researchers discover novel ACAT-2 inhibitors

June 21, 2010

Phase IIa trial of NU-1618 in hyperuricemia meets primary endpoint

June 18, 2010

Abbott and Neurocrine join to develop elagolix for endometriosis

June 18, 2010

Amylin, Lilly and Alkermes report on DURATION-4 trial of Bydureon

June 16, 2010

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

FDA clears phase I/II alpha-1-antitrypsin trial in type 1 diabetes

June 16, 2010

Chiasma reports on phase I trial of oral octreotide acetate

June 16, 2010

Boehringer Ingelheim discovers new 5-HT2C receptor agonists

June 16, 2010

Agile Therapeutics secures funds to advance AG-200-15 and AG-1000

June 15, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...